A phase II study of first-line gefitinib for advanced and recurrent EGFR mutation positive non-small cell lung cancer with high-risk factors.

Trial Profile

A phase II study of first-line gefitinib for advanced and recurrent EGFR mutation positive non-small cell lung cancer with high-risk factors.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jul 2017

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 28 May 2015 Status changed from recruiting to active no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top